"Designing Growth Strategies is in our DNA"

Lung Cancer Diagnostics Market Size, Share & Industry Analysis, By Cancer Type (Non-Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC)), By Test (Imaging Tests, Sputum Cytology, Biopsy, Molecular Tests, Other tests), By End User (Hospitals, Specialty Clinics, Others) Others and Regional Forecast, 2021-2028

Region : Global | Report ID: FBI102003 | Status : Ongoing

 

KEY MARKET INSIGHTS

Lung cancer is caused due to uncontrolled growth of cells, which can lead to development of a mass known, usually known as tumours. Lung cancers can usually initiate in any part of the lung, but the majority of cancers of the lung arise from the cells lining the larger and smaller airways (bronchi and bronchioles); for this reason, lung cancers are also referred as bronchogenic cancers or bronchogenic carcinomas. The major cause of lung cancer is strongly correlated with cigarette smoking, with about 90% of lung cancers arising because of tobacco use. Other causes include the presence of lung disease, prior history of lung cancer, air pollution, individual genetic susceptibility. Symptoms of lung cancer are varied depending upon where and how widespread the tumour is. Some common symptoms of the lung cancer include shortness of breath, headache, coughing up blood, chest pain, dysphagia, etc.


Key Market Driver -

Increasing demand for better diagnostics techniques, rising prevalence of lung cancer

Key Market Restraint -

High cost of diagnostics, side effects associated with imaging solutions


The global lung cancer diagnostic market growth is being driven by the rising prevalence of lung cancer, the introduction of technological advancements with regard to accuracy, and the growing awareness levels amongst the population across all the regions. Moreover, the availability of private & government funds for R&D to develop better tumor diagnostic tools are also projected to drive the growth of the lung cancer diagnostics market during the forecast period. For instance, In June 2019, first in vitro diagnostic immunohistochemistry (IHC) assay was launched by Roche Diagnostics to provide improved detection of lung cancer However, the untoward effects associated with imaging solutions and high cost of diagnosis are anticipated to hinder market growth.


Market Segmentation:


By cancer type, the market is segmented into non-small cell lung cancer NSCLC) and small cell lung cancer (SCLC). By test type, the market is segmented into imaging tests, sputum cytology, biopsy, molecular test, and other tests. By end users, the market is segmemted into hospitals, specialty clinics, and others.


By geographic standpoint, the liver cancer treatmement market is segmented into North America, Europe, Asia Pacific, Latin America and the Middle East & Africa.


Key Players Covered:


Some of the major companies that are present in the lung cancer diagnostics market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, AstraZeneca plc, Illumina Inc., Agilent Technologies, Inc. Qiagen, and others.


Key Insights



  • Prevalence of Lung Cancer for Key Countries,2018

  • New Product Launches in Lung Cancer Diagnostics Market, by Key Players

  • Technological Advancements in Global Lung Cancer Diagnostics market

  • Recent Industry Developments Such as Partnerships, Mergers, and Acquisitions


Regional Analysis:


To gain extensive insights into the market, Request for Customization


North America is expected to dominate the global lung cancer diagnostics market over the forecast period, followed by Europe. The dominance is majorly attributed to the high market penetration rates of technologically advanced diagnostic products, the rising patient awareness, and the rising smoking prevalence level in the region. Asia Pacific is likely to have a lucrative growth in the lung cancer diagnostics market in the forecast period due to the rising prevalence of lung cancer, and improvement in the research and development of diagnostic tools. Latin America and Middle East America are also expected to have a substantial growth in the lung cancer diagnostics market.


Segmentation


























 ATTRIBUTE


 DETAILS

By Cancer Type




  • Non-Small Cell Lung Cancer(NSCLC)

  • Small Cell Lung Cancer(SCLC)



By Test




  • Imaging Tests

  • Sputum Cytology

  • Biopsy

  • Molecular Tests

  • Other tests



By End User




  • Hospitals

  • Specialty Clinics

  • Others



By Geography




  • North America (USA and Canada)

  • Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

  • Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

  • Latin America (Brazil, Mexico and Rest of Latin America)

  • Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)



Lung Cancer Diagnostics Industry Developments



  • In June 2019, first in vitro diagnostic immunohistochemistry (IHC) assay was launched by Roche Diagnostics with an aim to offer improved detection of lung cancer.

  • In May 2019, Biocept launched Target Selector NGS Lung Panel assay. The newly launched devices can be used to perceive and analyse actionable biomarkers which are related with lung cancer.

  • In November 2018, Biocartis Group announced a strategic agreement with AstraZeneca with an aim to improve the lung cancer diagnostics in Europe with the help of molecular diagnostic biomarker results in Europe.


Lung Cancer Diagnostics Market Size, Share and Global Industry Trend Forecast till 2026
  • Ongoing
  • 2020
  • 2017-2019

    CHOOSE LICENSE TYPE

  • 4850
    6850
    8850

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Healthcare Clients

Lek
Jubilant
uniliver
Fresenius
Amgen

Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X